Review: Cannabinoids Show Anti-Inflammatory Potential Across Alzheimer's, Parkinson's, ALS, and MS

A review found cannabinoids have significant therapeutic potential for neurodegenerative and neuroinflammatory diseases due to their dual ability to modulate both neural and immune functions across multiple pathological mechanisms.

Tomaszewska-Zaremba, Dorota et al.·International journal of molecular sciences·2025·lowNarrative Review
RTHC-07807Narrative Reviewlow2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Narrative Review
Evidence
low
Sample
Not reported

What This Study Found

Cannabinoids show anti-inflammatory therapeutic potential across Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and HIV-associated dementia. Their broad spectrum of action allows targeting multiple pathological mechanisms simultaneously, including neuroinflammation, oxidative stress, and immune dysregulation.

Key Numbers

Conditions reviewed: Alzheimer's, Parkinson's, ALS, Huntington's, multiple sclerosis, HIV-associated dementia. Mechanisms: neuroinflammation, immune modulation, neuroprotection, oxidative stress reduction.

How They Did This

Narrative review of cannabinoid anti-inflammatory properties across neurodegenerative and CNS inflammatory conditions. Focused on preclinical and clinical evidence for each condition.

Why This Research Matters

Neurodegenerative diseases and CNS inflammatory conditions share overlapping immune-mediated pathology. Cannabinoids unique ability to simultaneously modulate both neural and immune functions positions them as potential multi-target therapeutics for conditions where single-mechanism drugs have failed.

The Bigger Picture

The failure of single-target drugs for neurodegenerative diseases has driven interest in multi-target approaches. Cannabinoids naturally engage multiple protective mechanisms, making them attractive candidates for conditions where neuroinflammation drives disease progression.

What This Study Doesn't Tell Us

Narrative review without systematic methodology. Much evidence is preclinical. Clinical trial data for cannabinoids in most neurodegenerative diseases is limited. Anti-inflammatory effects may not translate to disease modification in humans.

Questions This Raises

  • ?Which cannabinoid formulations are most promising for each neurodegenerative condition?
  • ?Can cannabinoid anti-inflammatory effects modify disease progression or only manage symptoms?

Trust & Context

Key Stat:
Evidence Grade:
Comprehensive narrative review spanning multiple conditions, but largely preclinical evidence with limited clinical trial data for most conditions.
Study Age:
2025 publication.
Original Title:
Anti-Inflammatory Effects of Cannabinoids in Therapy of Neurodegenerative Disorders and Inflammatory Diseases of the CNS.
Published In:
International journal of molecular sciences, 26(14) (2025)
Database ID:
RTHC-07807

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research without a strict systematic method.

What do these levels mean? →

Frequently Asked Questions

Can cannabinoids help with neurodegenerative diseases?

This review found cannabinoids have anti-inflammatory properties relevant to Alzheimer's, Parkinson's, ALS, Huntington's, MS, and HIV-associated dementia. Their ability to modulate both neural and immune functions simultaneously makes them promising candidates, though most evidence is still preclinical.

How do cannabinoids protect the brain?

Cannabinoids can reduce neuroinflammation, modulate immune responses, and protect neurons from oxidative stress. This review found these multi-target properties may be particularly valuable for neurodegenerative diseases where single-mechanism drugs have failed.

Read More on RethinkTHC

Cite This Study

RTHC-07807·https://rethinkthc.com/research/RTHC-07807

APA

Tomaszewska-Zaremba, Dorota; Gajewska, Alina; Misztal, Tomasz. (2025). Anti-Inflammatory Effects of Cannabinoids in Therapy of Neurodegenerative Disorders and Inflammatory Diseases of the CNS.. International journal of molecular sciences, 26(14). https://doi.org/10.3390/ijms26146570

MLA

Tomaszewska-Zaremba, Dorota, et al. "Anti-Inflammatory Effects of Cannabinoids in Therapy of Neurodegenerative Disorders and Inflammatory Diseases of the CNS.." International journal of molecular sciences, 2025. https://doi.org/10.3390/ijms26146570

RethinkTHC

RethinkTHC Research Database. "Anti-Inflammatory Effects of Cannabinoids in Therapy of Neur..." RTHC-07807. Retrieved from https://rethinkthc.com/research/tomaszewska-zaremba-2025-antiinflammatory-effects-of-cannabinoids

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.